An ongoing dialogue on HIV/AIDS, infectious diseases,
February 13th, 2013
Medication Adherence: The Final Frontier
Treatment of HIV has become so amazingly effective that when it fails, it’s no overstatement to say that it’s usually because the patient is not taking the medications. There are all kinds of provider-related reasons for this — inadequate patient education, prescribing and dispensing errors, failure to address language or education deficits — but here I want to focus on the patient-related causes.
In other words, on non-adherence.
(This used to be called “non-compliance.” That term has become un-PC; for some reason non-adherence is viewed as nicer. Please explain.)
Non-adherence in HIV care comes in a variety of flavors, including:
- Denial — “I feel fine, so why should I take those medicines? Yes, you tell me I have HIV, but I don’t really believe it’s a dangerous condition, or even that I have it, since as I said, I feel fine.“
- Stigma — “I won’t take those medications because each dose reminds me that I have HIV. And that makes me feel awful again and again, so until we can solve that problem, no chance I’m taking HIV meds.”
- Chaos — “You say I should take these medications, but how can I do so when my life is so horribly complicated because of family issues [or addiction or other medical problems or psychiatric disease or homelessness or …], so I’m going to ignore that recommendation to go on meds, and take my chances.”
- Deceit — “I’m taking the medications exactly as you prescribed. I rarely, if ever, miss a dose. Yes, my pharmacy told you I have not refilled my one-month supply of meds since 2009, but that doesn’t change the fact that I’m taking the medications exactly as prescribed. I told you that already.”
- Hypersensitivity — “I get side effects to everything. Literally everything. So I might leave the office today with a prescription, but I won’t fill it, because it will make me sick. Look, when I told you this, and you said that all medicines might have side effects, you proved my point.”
- Sicko — “Sure, I’ll take the medications if insurance covers the cost. But I lost my insurance, so rather than investigate getting on COBRA or an AIDS Drug Assistance Plan (ADAP) or some other program to keep me covered, I just stopped my meds. And that was 6 months ago.”
I’m sure there are others, but this list covers most of them. Note that these are not mutually exclusive, and some of the knottiest adherence problems come when more than one of the above is operative. Note also that I’m not counting the people who simply disappear from care — the “engagement in care” or “linkage” issue — which is a huge problem and responsible for lots of the drop-off in the infamous treatment cascade.
But the multifactorial nature of poor adherence is one reason why studies of adherence interventions so often have negative results. How can any single intervention address all of these factors?
Another reason for the negative studies is that the vast majority of patients do take their antivirals correctly — and this good med-taking behavior is probably especially common among those with the wherewithal to sign an informed consent for a clinical study. Most of these folks don’t need any help at all, so the intervention looks no better than the control; this study is an excellent example.
Yet if we can’t identify ahead of time the small fraction of our patients who will be non-adherent — and study after study says we can’t — how can we target our interventions to the people who need them the most?
(Next up: An Adherence Intervention that Actually Works — But There’s a Catch)
Categories: Health Care, HIV, Infectious Diseases, Patient Care, Research
Tags: adherence, antiretroviral therapy, HIV
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
4 Responses to “Medication Adherence: The Final Frontier”
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
-
From the Blog — Most Recent Articles
- ID Things to Be Grateful for — 2025 Edition November 24, 2025
- When AI Gets the Medical Advice Wrong — and Right November 18, 2025
- Hot Takes from IDWeek: CDC, COVID, and Two Doses of Dalbavancin November 13, 2025
- Favorite ID Fellow Consults: Johns Hopkins Edition November 7, 2025
- Two Covid Vaccine Studies — One Actionable, the Other Not So Much October 28, 2025
FROM NEJM — Recent Infectious Disease Articles- Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk December 4, 2025Highly pathogenic avian influenza A(H5N1) virus has spread among dairy cattle, with virus detected in milk samples. In this report, virus viability after cold storage or pasteurization is assessed.
- Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026 December 4, 2025Results from recently published, peer-reviewed studies support the safety and effectiveness of immunizations against Covid-19, RSV, and influenza.
- Glucocorticoids for Pneumonia in Africa — Old Therapy, New Context December 4, 2025The African continent is home to 1.55 billion people, one fifth of the world’s population, spread over an area larger than the United States, China, and India combined. The disease burden is enormous,1 and health care resources are severely constrained. In one multinational survey, one in eight hospitalized...
- The New U.S. Global Health Strategy — A Reset of America’s Health Cooperation December 4, 2025The U.S. administration recently unveiled its new approach to global health. A retreat from multilateralism, a geopolitical emphasis, and rushed transitions could threaten progress.
- Empyema Necessitans December 4, 2025A 66-year-old man presented with 2 weeks of shortness of breath and cough, 5 days of left flank pain, and 2 days of a rapidly expanding mass on his left side.
- Stability of Avian Influenza A(H5N1) Virus in Milk from Infected Cows and Virus-Spiked Milk December 4, 2025
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster


t’s great to have a classification like that. I’m currently working with someone who is a combination of 1 and 3 and 5. Hypersensitivity may not be the exact term, more like intolerance. It’s true it must be hard to take meds every day that make you feel lousy, when missing will only kill you in the distant future which can seem very far.
I have lost a few patients just because they wouldn’t take their meds for any of the reasons you listed. I always say to myself that in some countries, they’d give anything to have access to these meds, but here, psychosocial issues seem to be part of the HIV epidemic. Maybe we should have some of the “deniers” watch a movie with endstage patients on it (since these patients are not so visible anymore), and cartoons of rapidly replicating virions, and sign off that they saw the movie and understand what the consequences of nonadherence are.
Best, Michèle
Where would cognitive disability be classified. This weekend I had a patient that knows he has HIV but does not know recall the medications he takes, runs away from home on a constant basis, leaving family frantically looking for him. He cannot be institutionalized or which institution would take him. He shows up at Emergency room,time and time again, returns home and repeats the cycle. His popular phrase is “sorry I donot remember’ to almost everyone question.
Also a major problem is under-diagnosed, or poorly treated mental health disorders. Until there are better ways to link our patients to mental health providers with experience in treating HIV patients, this will continue to be a huge problem.
Sadly #6 is more + more common these days, with the economic downturn + the expense of the medications to the State. I need to start keeping track every time one of my patients shows up off meds due to “insurances issues.” Medicaid managed care plans now contract with pharmacy benefit managers — giant for-profit corporations — to create an extremely complex system that is a challenge for even health care professionals to navigate, much less the marginalized population these companies are supposedly “managing.” I know you agree and read your recent Annals article on generics to save $1B and know you meant to say “despite all efforts to investigate” instead of blaming the patients for this dangerous new trend. Thanks and apologies for the criticism b/c I know this blog is supposed to be fun!